Esthesioneuroblastoma

Abstract

Patients: Fifty consecutive patients diagnosed as having esthesioneuroblastoma were treated with a standardized protocol during a 28-year period. Patients with tumors staged Kadish A or B received preoperative radiotherapy followed by craniofacial resection, while patients with Kadish stage C disease were treated with preoperative sequential chemotherapy and radiotherapy followed by a craniofacial resection. The mean follow-up is 93 months (range, 1-330 months). Results:The disease-free survival was 86.5% and 82.6% at 5 and 15 years, respectively. There were 17 patients (34%) who developed recurrent disease, most of which was locoregional (12 patients [71%]). There was a long interval to relapse (mean, 6 years), with the longest time to regional recurrence being 10 years. Distant relapses occurred sooner, with poorer outcomes. Of these 17 patients, 7 (41%) underwent successful salvage surgery, while 3 remain alive with disease.

Esthesioneuroblastoma: A case with prolonged disease control

“…In a study reported by a group from the University of Virginia, patients with Kadish stage C received preoperative sequential chemotherapy (two cycles of vincristine + cyclophosphamide ± doxorubicin) and radiation therapy, followed by craniofacial resection. The 5-and 15-years survival rates reported for this group were 72% and 60%, respectively [12] , which are similar to other values reported without the use of chemotherapy [3,10] . There is limited experience in the metastatic setting owing to the rarity of this subset of patients.…”

The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck

“…With a median follow up time of 82.3 months, patients with ENB can experience disease recurrence even 10-years after completion of their initial treatment. 4, 20–22 As such, while we observed a trend towards improved neck control with ENI, this difference may become significant with longer follow-up. Unfortunately, overcoming the aforementioned limitations is difficult given the rarity and natural history of ENB.…”

Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients

“…Further studies are required to determine whether chemotherapy is necessary, consistent with previous studies [19–22]. Moreover, the value of neoadjuvant chemoradiotherapy was not assessed in this study due to the small number of patients (only seven) receiving this treatment modality, limiting our ability to make meaningful comparisons with this subgroup, though previous studies have shown neoadjuvant chemoradiotherapy provides a survival benefit [23–25]. After reviewing our data and the literature, we suggest that combined modality treatment (surgery and radiotherapy) may significantly decrease recurrence and improve OS and DFS in ENB.…”